PFIZER INC

Pfizer shares dip amid a market sell‑off, yet the pharma giant’s solid earnings, R&D pipeline, and regulatory progress keep investors focused on its long‑term value.

Explore Pfizer’s post‑pandemic cash‑flow dynamics, its new obesity drug strategy, and how tariff policy shifts could shape its future returns.

Pfizer balances post‑pandemic cash flow with a bold biosimilars expansion—targeting oncology mAbs, cutting manufacturing costs, and securing FDA/EMA approvals to sustain shareholder value.

Explore how Pfizer’s recent phantom‑stock exercise and self‑managed proxy voting reveal its approach to executive incentives, governance, and ESG pressures—insights for investors and analysts alike.

U.S. expands most‑favored‑nation drug‑pricing agreements to nine new pharma firms, promising Medicaid cost savings and tariff relief for key medicines.

Pfizer’s small ETF outflow shows smart portfolio shifts, not weakness—yet the pharma giant’s robust cash flow, digital health partnerships, and value‑based contracts keep it poised for future growth.

Explore how Pfizer’s first‑half 2026 results show partnership-driven growth, milestone‑payment impact, and pipeline prospects amid margin pressure.

Pfizer’s 1H 2026 results show strong earnings driven by milestone income from the SSGJ‑707 partnership, alongside growing oncology and obesity revenues, positioning the company for sustained growth.

Pfizer’s Q1 earnings reveal oncology & obesity growth, cost‑saving plans, and a shift from COVID‑19 sales, boosting share price and long‑term prospects.

Explore Pfizer’s latest corporate moves—from phantom stock exercises to global licensing deals—and learn how these actions impact investor value, governance, and litigation risks.